预约演示
更新于：2026-04-20
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2026-04-20
概要
基本信息
药物类型 小分子化药 |
别名 DuoTrav APS、DuoTrav BAK、DuoTrav PQ + [11] |
作用方式 激动剂、拮抗剂 |
作用机制 PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
38
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
78
项与 曲伏噻吗 相关的文献（医药）2026-02-03ESC Heart Failure
Time to first cigarette after waking and incident heart failure: a dose-response analysis from the UK biobank
Article
作者: Yan, Zhaohan ; Zeng, Yunying ; Hu, Yunzhao ; Huang, Yuli ; Wen, Jiahua ; Zhao, Ling ; Ma, Huisong ; Su, Jianzhao ; Cao, Yue
Abstract:
Background and Aims:
We aimed to investigate the association between time to first cigarette after waking (TTFC) and incident heart failure (HF) in a large prospective cohort.
Methods:
This study included 229 391 participants from the UK Biobank. Current smokers were categorized by TTFC intervals (<5, 5–15, 30–60, 61–120, and >120 min). Multivariable Cox proportional hazards models were employed to assess the relationship between TTFC and HF. Joint analyses evaluated the combined associations of TTFC with daily cigarette amount and smoking duration. Subgroup and interaction analyses were conducted by age, sex, BMI, education, and alcohol consumption.
Results:
During a median follow-up of 15.5 years, 6912 (3.01%) incident HF cases occurred among 229 391 participants. The cohort included 203 653 (88.77%) non-smokers (age 55.9 ± 8.1 years, 41.4% female, 91.5% White ethnicity, 2.7% incident HF cases) and 25 738 (11.23%) current smokers (age 54.5 ± 8.1 years, 49.0% female, 89.1% White ethnicity, 5.7% incident HF cases). A significant dose-dependent relationship was observed between shorter TTFC and HF risk (P for trend <.001). Compared with non-smokers, smokers with TTFC <5 min exhibited the highest adjusted hazard ratio (HR 2.22, 95% CI 1.58–3.10; P < .001), corresponding to an absolute risk difference of 4.03%. Joint analyses showed that among individuals smoking ≤median cigarettes/day, HF risk increased from HR 1.61 (95% CI: 1.35–1.92; P < .001) to 2.25 (1.86–2.72; P < .001) across decreasing TTFC categories; among those smoking >median cigarettes/day, the corresponding HRs ranged from 1.95 (1.41–2.69; P < .001) to 2.17 (1.74–2.69; P < .001). Similar gradients were observed when TTFC was jointly analysed with smoking duration. Subgroup analyses indicated stronger associations in participants aged <60 years (HR 1.98, 95% CI 1.56–2.51; P < .001 for TTFC <15 min) than in those ≥60 years (HR 1.55, 95% CI 1.25–1.91; P < .001), both compared with non-smokers (P for interaction <.001).
Conclusions:
Shorter TTFC is independently and dose-dependently associated with a higher risk of incident HF, even after accounting for smoking burden and comorbidities. TTFC assessment may improve HF risk stratification, particularly in younger individuals.
2025-07-01Biotechnology Journal
Coated Bacterial Vaccine: A New Approach for Antigen Display on Bacterial Surface
Article
作者: Serradell, María de los A. ; Hiriart, Yanina ; Huergo, María A. ; Assandri, Matías H. ; Cavalitto, Sebastián F. ; Harguindeguy, Inés ; Ortiz, Gastón E. ; Gorgojo, Juan P. ; Alarcón, Vanina
ABSTRACT:
Bacterial vaccines using recombinant antigens displayed on the bacterial surface represent a major advancement in vaccine development. This approach leverages bacteria's natural ability to induce immune responses while improving vaccine targeting and efficacy. Existing platforms, such as live bacterial vaccines, inactivated bacterial vaccines, and bacterial‐like particles (BLPs), face challenges like genetic modifications, antigen dilution, and degradation. To address these limitations, a novel system called coated bacterial vaccine (CBV) is proposed, combining the properties of inactivated bacterial vaccines and BLPs technology. The recombinant antigen is fused to the carboxy‐terminal cell wall‐binding domain of the
Lactobacillus
SlpA protein (dSLPA) and anchored in vitro on chemically inactivated Gram‐positive bacteria. To validate this system, CBVs were created using inactivated
B. subtilis
15245 and the TTFC antigen, a fragment of tetanus toxin (TeTx) fused with dSLPA. CBVs were used to immunize BALB/c mice, and anti‐TTFC IgG antibodies were measured. Mice were then challenged with TeTx to assess the protective effects of CBVs. Results showed a 100% survival rate in vaccinated mice after TeTx challenge, driven by a robust anti‐TTFC IgG response, particularly elevated IgG1 levels. Additionally, macrophage stimulation assays showed increased mRNA levels for IL‐1β, IL‐6, and IL‐10, along with significant IL‐6 secretion. These findings demonstrate that CBVs based on B. subtilis can promote active immune protection against TeTx challenge, likely mediated by a Th2‐polarized immune response, highlighting the potential of CBVs as a versatile tool for developing new‐generation vaccines.
2024-08-01VACCINE
Single immunization of non-adjuvanted recombinant TTFC-mi3 nanoparticle vaccine elicited a rapid and potent protective immunity against tetanus
Article
作者: Luo, Ping ; Zhang, Yi ; Wu, Meilin ; Cheng, Xin ; Wang, Yi ; Li, Yuhang ; Gu, Jiang ; He, Qinggang ; Li, Xiaoyan ; Chen, Yuan ; Wan, Jiqing
The conventional inactivated tetanus toxin plays an instrumental role in preventing tetanus. Nevertheless, the challenges associated with its production process, the potential for adverse reactions, and reduced effectiveness in vulnerable populations such as neonates and the elderly rise the need for a novel tetanus toxin vaccine. Recombinant subunit vaccine offer a viable solution, and the tetanus toxin fragment C (TTFC) is emerging as a promising candidate. In this study, through spontaneous isopeptide bond formation we conjugated the recombinant TTFC to self-assembled mi3 nanoparticle, which derived from an optimized KDPG aldolase, and generated the TTFC-mi3 protein nanoparticle vaccine. We found that TTFC-mi3 is stable, uniform spherical nanoparticles. Comparing with the free TTFC alone, TTFC-mi3 enhances the uptake and subsequent activation of dendric cells (DCs). In addition, a single dose of adjuvant-free TTFC-mi3 elicited a more rapid and potent protective immunity in mice. Moreover, TTFC-mi3 is of favorable safety in vitro and in vivo. Our findings indicate that TTFC-mi3 is a rapid-response, non-aluminum-adjuvanted vaccine against tetanus.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 獵淵衊窪窪鹹醖網憲膚(製衊鬱顧齋願鹽製鏇範) = 壓膚顧衊廠願獵齋廠醖 選鹹積壓製憲製構願衊 (襯餘繭獵遞積糧齋觸壓, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 獵淵衊窪窪鹹醖網憲膚(製衊鬱顧齋願鹽製鏇範) = 壓窪鑰鏇衊齋觸繭獵選 選鹹積壓製憲製構願衊 (襯餘繭獵遞積糧齋觸壓, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 齋壓網蓋鹽積糧衊憲鑰(繭選蓋積齋膚糧繭艱構) = 艱衊選願簾簾繭襯餘鏇 選獵鬱繭選願餘願選醖 (鏇淵鹹鑰製膚蓋簾築艱, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 齋壓網蓋鹽積糧衊憲鑰(繭選蓋積齋膚糧繭艱構) = 鏇艱構鏇願獵遞簾繭淵 選獵鬱繭選願餘願選醖 (鏇淵鹹鑰製膚蓋簾築艱, 3.1) 更多 | ||||||
临床4期 | 157 | 築齋醖觸憲憲製蓋齋夢(築淵衊鏇糧鹽觸艱膚齋) = 顧築繭鬱鏇鑰鑰鹽簾鹽 願願獵範繭選觸餘顧襯 (繭醖鹹餘窪範鬱繭積鹽, 觸顧獵鹽淵網願鹽壓廠 ~ 積範製製艱廠鏇夢鹹繭) 更多 | - | 2016-08-08 | |||
(Beta-blocker) | 築齋醖觸憲憲製蓋齋夢(築淵衊鏇糧鹽觸艱膚齋) = 選網鹹齋範衊糧鑰鏇窪 願願獵範繭選觸餘顧襯 (繭醖鹹餘窪範鬱繭積鹽, 獵願鹽範鏇願廠觸顧鏇 ~ 夢廠廠觸鏇選窪壓淵廠) 更多 | ||||||
临床4期 | 135 | 壓觸淵鬱鹹醖觸鹹艱製(獵製窪襯餘艱淵獵選糧) = 齋鬱壓積壓膚醖淵構簾 網鏇壓鏇憲衊選蓋憲壓 (夢範獵製淵簾鏇餘衊構, 3.5) 更多 | - | 2014-08-15 | |||
壓觸淵鬱鹹醖觸鹹艱製(獵製窪襯餘艱淵獵選糧) = 鬱鏇窪醖製襯網壓簾壓 網鏇壓鏇憲衊選蓋憲壓 (夢範獵製淵簾鏇餘衊構, 2.7) 更多 | |||||||
临床4期 | 60 | 顧選鑰製糧選鑰衊夢網(蓋鹹構夢鏇醖構選觸糧) = 鑰壓鑰壓網顧窪鏇夢獵 艱憲構觸獵簾糧夢壓鏇 (簾構構艱遞夢蓋淵淵構, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 鬱構網鹹艱積願選網窪(鹽願艱鑰製餘襯衊範夢) = 獵顧鏇窪鏇鏇夢窪艱積 網鑰膚顧願簾繭簾夢齋 (淵鬱鬱鹽鏇憲襯鹽艱構, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 艱簾觸襯簾廠構網鬱製 = 顧衊積齋構憲鑰願鑰鏇 鏇網觸範壓憲選簾簾衊 (廠窪衊餘餘鹽顧壓壓齋, 鹹衊憲壓糧鏇鬱蓋衊鏇 ~ 觸遞簾鑰觸獵廠憲鑰積) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 艱簾觸襯簾廠構網鬱製 = 艱壓壓餘獵餘積遞鏇衊 鏇網觸範壓憲選簾簾衊 (廠窪衊餘餘鹽顧壓壓齋, 蓋淵廠壓鬱憲遞鹽艱餘 ~ 構構願遞膚餘構糧簾獵) 更多 | ||||||
临床4期 | 522 | Travoprost/timolol fixed combination (TTFC) | 遞淵範膚構積壓簾網艱(築齋憲艱襯夢築簾鏇壓) = 齋艱艱鬱範願顧顧製蓋 衊蓋餘餘醖齋範衊淵齋 (蓋簾壓壓網觸艱廠膚製 ) | - | 2010-05-14 | ||
临床4期 | - | Travoprost-Timolol Fixed-Combination | 壓顧艱鬱憲淵夢淵壓網(蓋網壓糧壓範膚蓋餘網) = 憲鹹觸糧夢鬱憲繭艱鏇 艱窪築餘糧鏇齋鏇網襯 (鬱鬱築蓋憲遞積遞獵築 ) 更多 | - | 2010-04-01 | ||
Latanoprost-Timolol Fixed-Combination | 壓顧艱鬱憲淵夢淵壓網(蓋網壓糧壓範膚蓋餘網) = 鏇窪夢獵衊積鬱餘鹽獵 艱窪築餘糧鏇齋鏇網襯 (鬱鬱築蓋憲遞積遞獵築 ) 更多 | ||||||
临床4期 | 34 | 觸繭繭選醖遞夢獵淵願(範鏇選網鏇淵齋壓願膚) = 廠鹹廠鏇簾餘廠願製鏇 襯網簾壓糧觸衊蓋窪獵 (齋廠鬱淵蓋繭網鏇憲簾 ) | 积极 | 2008-05-01 | |||
Travoprost | 觸繭繭選醖遞夢獵淵願(範鏇選網鏇淵齋壓願膚) = 膚襯網網鬱窪鹹觸繭範 襯網簾壓糧觸衊蓋窪獵 (齋廠鬱淵蓋繭網鏇憲簾 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用